USLLY Recent Stock News Investing - MSN Money

[Guest guest]

Could this work on all herpes virues.?

http://news.moneycentral.msn.com/ticker/article.asp?Feed=BW & Date=20010925 & ID=108\

8778 & Symbol=US:LLY

[Guest guest]

> Could this work on all herpes virues.?

>

Hi Carol,

This treatment sounds like good news to me. Given that it is an

immune modulator, I think that increases the odds that it will be

helpful against the herpes family of viruses. It might be very good

news for us. Too bad we can't get our hands on it for three years.

Luke

Resiquimod is one of a new family of immune response modifier (IRM)

molecules developed by 3M Pharmaceuticals, of which Aldara

(imiquimod) is the first compound to have been marketed globally.

IRMs act in a novel way to stimulate the human body's immune system

to fight viral infections

W. Benson, executive vice president, 3M Health Care Markets,

said, " Today's announcement is yet another exciting development for

this new-to-the-world class of compounds with the potential to change

the practice of medicine. We are tremendously pleased to align with

Lilly on the development and commercialization of this promising new

herpes treatment. "

Resiquimod is expected to represent a major advance over currently

marketed therapies and address many unmet medical needs in the herpes

market, particularly genital herpes. Ongoing clinical trials suggest

that resiquimod significantly increases the time between genital

herpes outbreaks and may produce a long-lasting suppressive effect

without the need for daily therapy. Through its novel approach, some

clinical investigators believe resiquimod may potentially reduce

viral transmission and, with multiple courses of therapy, place the

disease into clinical remission. It is anticipated that a new drug

application will be submitted to the U.S. Food and Drug

Administration in 2004